Literature DB >> 20620544

Prolonged cardiac allograft survival using iodine 131 after human sodium iodide symporter gene transfer in a rat model.

D Ricci1, A A Mennander, N Miyagi, V P Rao, H D Tazelaar, K Classic, G W Byrne, S J Russell, C G A McGregor.   

Abstract

BACKGROUND: Radioiodine is efficiently concentrated by tissues expressing the human sodium iodide symporter (hNIS).
OBJECTIVE: To analyze the effects of iodine 131 on acute cardiac allograft rejection after ex vivo hNIS gene transfer in a rat model of cardiac allotransplantation.
MATERIALS AND METHODS: Hearts from Brown Norway rats were perfused ex vivo either with UW (University of Wisconsin) solution (n = 9) or UW solution containing 1 x 10(9) pfu/mL of adenovirus 5 plus NIS (Ad-NIS) (n = 18). Donor hearts were transplanted heterotopically into the abdomen of Lewis rats, and recipients were treated on postoperative day 3 with either 15,000 microCi of (131)I or saline solution. The hearts were explanted when no longer beating, and were evaluated histologically for evidence of rejection and other changes.
RESULTS: Grafts perfused with the Ad-NIS vector survived significantly longer in recipients injected with (131)I (mean [SD], 11.3 [1.9] days) compared with control animals not treated with (131)I (5.7 [0.65] days) (P < .001). Treatment with (131)I did not prolong graft survival in recipients of hearts that were not perfused with Ad-NIS (5.5 [1.0] vs 5.3 [0.8] days). In Ad-NIS (131)I-treated transplants, the level of myocardial damage on day 6 after surgery, when control hearts were rejected, was significantly lower (60.8 [28.0] vs 99.7 [0.8]; P < .05).
CONCLUSION: Our findings indicate that (131)I, after NIS gene transfer, can effectively prolong cardiac allograft survival. To our knowledge, this is the first report of the use of NIS-targeted (131)I therapy in cardiac transplantation. Further studies are required to determine the mechanism of this effect and its potential for clinical application.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20620544      PMCID: PMC2904983          DOI: 10.1016/j.transproceed.2009.12.065

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  35 in total

1.  Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection.

Authors:  Susan Stewart; Gayle L Winters; Michael C Fishbein; Henry D Tazelaar; Jon Kobashigawa; Jacki Abrams; Claus B Andersen; Annalisa Angelini; Gerald J Berry; Margaret M Burke; Anthony J Demetris; Elizabeth Hammond; Silviu Itescu; Charles C Marboe; Bruce McManus; Elaine F Reed; Nancy L Reinsmoen; E Rene Rodriguez; Alan G Rose; Marlene Rose; Nicole Suciu-Focia; Adriana Zeevi; Margaret E Billingham
Journal:  J Heart Lung Transplant       Date:  2005-06-20       Impact factor: 10.247

2.  The MIRD perspective 1999. Medical Internal Radiation Dose Committee.

Authors:  R W Howell; B W Wessels; R Loevinger; E E Watson; W E Bolch; A B Brill; N D Charkes; D R Fisher; M T Hays; J S Robertson; J A Siegel; S R Thomas
Journal:  J Nucl Med       Date:  1999-01       Impact factor: 10.057

3.  Unrestricted hepatocyte transduction with adeno-associated virus serotype 8 vectors in mice.

Authors:  Hiroyuki Nakai; Sally Fuess; Theresa A Storm; Shin-ichi Muramatsu; Yuko Nara; Mark A Kay
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

4.  Adenovirus-mediated and targeted expression of the sodium-iodide symporter permits in vivo radioiodide imaging and therapy of pancreatic tumors.

Authors:  Roisin M Dwyer; Elizabeth R Bergert; Michael K O'Connor; Sandra J Gendler; John C Morris
Journal:  Hum Gene Ther       Date:  2006-06       Impact factor: 5.695

5.  AAV serotype-1 mediates early onset of gene expression in mouse hearts and results in better therapeutic effect.

Authors:  H Su; Y Huang; J Takagawa; A Barcena; J Arakawa-Hoyt; J Ye; W Grossman; Y W Kan
Journal:  Gene Ther       Date:  2006-06-15       Impact factor: 5.250

6.  Treatment with rhenium-188-perrhenate and iodine-131 of NIS-expressing mammary cancer in a mouse model remarkably inhibited tumor growth.

Authors:  Ekaterina Dadachova; Andrew Nguyen; Elaine Y Lin; Leo Gnatovskiy; Ping Lu; Jeffrey W Pollard
Journal:  Nucl Med Biol       Date:  2005-10       Impact factor: 2.408

7.  Sodium iodide symporter-mediated radioiodide imaging and therapy of ovarian tumor xenografts in mice.

Authors:  R M Dwyer; E R Bergert; M K O'Connor; S J Gendler; J C Morris
Journal:  Gene Ther       Date:  2006-01       Impact factor: 5.250

8.  Robust systemic transduction with AAV9 vectors in mice: efficient global cardiac gene transfer superior to that of AAV8.

Authors:  Katsuya Inagaki; Sally Fuess; Theresa A Storm; Gregory A Gibson; Charles F Mctiernan; Mark A Kay; Hiroyuki Nakai
Journal:  Mol Ther       Date:  2006-05-19       Impact factor: 11.454

9.  Radioisotope concentrator gene therapy using the sodium/iodide symporter gene.

Authors:  R B Mandell; L Z Mandell; C J Link
Journal:  Cancer Res       Date:  1999-02-01       Impact factor: 12.701

10.  In vivo quantitation of intratumoral radioisotope uptake using micro-single photon emission computed tomography/computed tomography.

Authors:  Stephanie K Carlson; Kelly L Classic; Elizabeth M Hadac; Claire E Bender; Bradley J Kemp; Val J Lowe; Tanya L Hoskin; Stephen J Russell
Journal:  Mol Imaging Biol       Date:  2006 Nov-Dec       Impact factor: 3.484

View more
  2 in total

1.  Biometric evidence of diet-induced obesity in Lew/Crl rats.

Authors:  Chad W Schmiedt; Robert M Gogal; Stephen B Harvey; Amanda K Torres; Carla L Jarrett; Elizabeth W Uhl; David J Hurley
Journal:  Comp Med       Date:  2011-04       Impact factor: 0.982

2.  Experimental cardiac radiation exposure induces ventricular diastolic dysfunction with preserved ejection fraction.

Authors:  Hirofumi Saiki; Gilles Moulay; Adam J Guenzel; Weibin Liu; Teresa D Decklever; Kelly L Classic; Linh Pham; Horng H Chen; John C Burnett; Stephen J Russell; Margaret M Redfield
Journal:  Am J Physiol Heart Circ Physiol       Date:  2017-05-26       Impact factor: 4.733

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.